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Abstract 
Objectives The objectives were: (1) to report the preliminary development of the Hormone 
deficiency-Dependent Quality of Life (HDQoL) questionnaire, a new individualised 
questionnaire in which respondents rate personally applicable domains for importance and 
impact of hormonal deficiency and its treatment; (2) to evaluate the HDQoL’s psychometric 
properties for adults with hypopituitarism including growth hormone deficiency (GHD).  
Methods Internal consistency reliability, aspects of validity, and sensitivity to change of the 
HDQoL were investigated in: (1) a cross-sectional survey of 157 adults with treated or 
untreated GHD; (2) a randomised, placebo-controlled study of three months’ growth 
hormone (GH) withdrawal from 12 of 21 GH-treated adults.  
Results Thirteen of the original 18 HDQoL domains were relevant and important for GH-
deficient adults.  The shorter 13-item HDQoL had excellent internal reliability (Cronbach’s 
alpha coefficient = 0.914, N = 109), and was sensitive to sex differences (cross-sectional 
study): women perceived worse present QoL than men [t(149.8) = 2.33, P = 0.021]. The 
HDQoL was sensitive to change (GH-Withdrawal study) with a significant between-group 
difference in change in domain scores for things I can do physically [t(16) = 2.47, P = 
0.025, 2-tailed], patients withdrawn from GH reporting greater negative impact of hormone 
deficiency on this domain at end-point. Qualitative work resulted in the addition of seven 
new HDQoL domains, including energy and bodily pain.   
Conclusion The HDQoL, although at an early stage of development, proved useful in 
identifying expected changes following GH withdrawal. The extended 20-item version is 
recommended for further evaluation in assessing the impact of hypopituitarism on QoL. 
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Introduction 
Hypopituitarism is a condition involving deficiencies in one or more of the eight pituitary 
hormones (for example growth hormone (GH), thyroid stimulating hormone, 
adrenocorticotrophic hormone, and antidiuretic hormone). The condition is most commonly 
caused by the presence of a pituitary adenoma and/ or its treatment (Smith 2004). 
Replacement of some hormones, e.g. corticosteroids and antidiuretic hormone, is 
mandatory to avoid life-threatening conditions, but GH replacement remains controversial 
as there is uncertainty whether the benefits outweigh the high financial costs and a 
treatment regimen requiring daily injections. The physical symptoms of adult growth 
hormone deficiency (GHD) include abnormal body composition with reduced lean body 
mass and increased central adiposity; reduced muscle strength and exercise performance 
(Carroll et al. 1998).  However, psychological symptoms may be as important as 
physiological (Powrie et al. 1995) and psychological variables need to be considered when 
assessing patients for GH replacement (Bengtsson et al. 2000).  Psychological symptoms 
reported by adults with untreated GHD include low energy, tiredness, sleepiness, poor 
concentration, poor memory, irritability (Hunt et al. 1993), anxiety, depression and mood 
swings (Wallymahmed et al. 1996).   
Sensitive measures of patient-reported outcomes are required in addition to clinical 
outcomes to assess the effects of GH treatment. The Nottingham Health Profile (NHP) 
(Hunt & McKenna 1989) and the Psychological General Well-being Index (PGWB) (Dupuy 
1984) were the most frequently used questionnaires to measure psychological symptoms 
in early studies of GH replacement in adult GHD. Some studies found improvements after 
six months’ GH treatment (McGauley et al. 1990; Mardh et al. 1994; Carroll et al. 1997), 
but others did not find significant effects (Whitehead et al. 1992; Baum et al. 1998) 
perhaps because such generic measures are insufficiently sensitive (Wiren et al. 2001). 
Condition-specific measures are usually more sensitive than generic, and the condition-
specific Quality of Life-Assessment of Growth Hormone Deficiency in Adults (QoL-
AGHDA) (McKenna et al. 1999) has been increasingly widely used (Ahmad et al. 2001; 
Malik et al. 2003; Svensson et al. 2004).  However, the QoL-AGHDA has been criticised 
on several grounds including the fact that respondents are not asked whether they 
attribute their reduced quality of life (QoL) to growth hormone deficiency, there is no time 
reference, and the response options are dichotomous, thus it is not possible to determine 
the degree of perceived impairment  (Barkan 2001; Barkan & Wren 2001).  Another 
questionnaire, Questions on Life Satisfaction, hypopituitarism module (QLS-H) (Henrich & 
Herschbach 2000), appears to be more specifically about satisfaction with aspects of 
health than QoL per se.   
 
This paper concerns the evaluation of the psychometric properties of a new condition-
specific measure of QoL in hypopituitarism: the Hormone deficiency-Dependent Quality of 
Life Questionnaire (HDQoL) (Bradley 1999).  The HDQoL offers a very different approach 
to the measurement of QoL from that of the QoL-AGHDA. QoL-AGHDA design assumes 
that all symptoms or experiences universally detract from QoL and that they are equally 
important to all respondents. The HDQoL uses an individualised approach, measuring the 
perceived impact of hormone deficiency on those aspects of life relevant to the individual, 
and allowing the individual’s view of the importance of each aspect of life for their QoL to 
influence the scores. The psychometric properties of the HDQoL were evaluated in two 
studies at St Thomas’ Hospital, London. (1) A cross-sectional survey of 157 adults with 
hypopituitarism including severe GHD, GH-treated or non-GH-treated, investigated internal 
consistency reliability, factor structure, and aspects of validity of the questionnaire. (2) A 
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randomised placebo-controlled study of three months’ withdrawal of GH treatment from 12 
of 21 GH-treated adults with hypopituitarism, where nine continued with GH, investigated 
sensitivity to change. The Guy’s and St Thomas’ Hospital Trust Ethics Committee gave 
approval for both studies. 
 
Methods  
Materials 
The HDQoL questionnaire  
Design of the HDQoL was based on the Audit of Diabetes-Dependent Quality of Life 
(ADDQoL) (Bradley et al. 1999; Bradley & Speight 2002) and a subsequent adaptation of 
the ADDQoL for renal patients, the RDQoL (Bradley 1997). The ADDQoL was influenced 
by the generic individualised interview method known as SEIQoL (Schedule for the 
Evaluation of Individual Quality of Life) (McGee et al. 1991).  Although, patients were 
involved in generating versions for diabetes and renal disease, time constraints prevented 
qualitative research in adult hypopituitarism and adjustments were made to the condition 
referred to in the RDQoL to make it suitable for patients with hypopituitarism, and one item 
deleted as it appeared to be irrelevant to hypopituitarism. The HDQoL was designed with 
18 domains covering work, family, social life, sex life, physical appearance, self-
confidence, physical capabilities, holidays/ leisure, travel, motivation, spiritual life, society’s 
reaction, worries about the future, finances, dependence, others fussing, living conditions, 
and freedom to eat as wished.  Being individualised, the HDQoL gives respondents the 
opportunity to indicate whether a particular domain is not applicable (N/A), specifically in 
questions concerning work, family, sex and religious life.  
 
The first section has two overview items.  Question A (QA:present QoL) asks people to 
rate their present QoL on a 7-point scale from ‘as good as it could possibly be’ to ‘as bad 
as it could possibly be’. Question B (QB:hormone deficiency-dependent QoL) asks people 
to rate what their QoL would be if they did not have hormone deficiency, on a 7-point scale 
from ‘very much better’ to ‘very much worse’. Each domain is introduced by the 
hypothetical statement: If I did not have hormone deficiency, my [domain] would be…… 
and is followed by a 7-point Likert scale from ‘very much better’ to ‘very much worse’ (the 
impact rating).  Respondents then rate how important that domain is to their QoL on a 
4-point Likert scale from ‘very important’ to ‘not at all important’. (Fig. 1 provides an 
example of a domain item and scores). There is also a ‘free comments’ section where 
patients may describe any other ways in which they perceive hormone deficiency and its 
treatment to affect their QoL. This section allows for the addition of further HDQoL 
domains in the future, as part of its continuing development. 
 
Scoring: A weighted domain score is obtained by multiplying the domain’s impact rating by 
the corresponding importance rating. An overall HDQoL score, the Average Weighted 
Impact score (HDQoL AWI), is obtained by summing all applicable weighted domain 
scores, before dividing by the number of domains applicable to the individual. Weighted 
domain scores and HDQoL AWI range from -9 to +9 (maximum negative to maximum 
positive impact of hormone deficiency on that domain or on overall QoL).  The overview 
items are not weighted by importance ratings. QB:hormone deficiency-dependent QoL is 
scored the same way as the impact ratings on the domains, from -3 to +3, but QA:present 
QoL is scored from +3 to -3, a lower score indicating poorer QoL. 
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Other questionnaires used in the studies 
Other questionnaires were also completed in these studies including the NHP, Short-form 
36 (SF-36) (Ware & Sherbourne 1992), General Well-being Index, (British version of the 
PGWB) (Hunt & McKenna 1992) and the Well-being Questionnaire (Bradley 1994), the full 
results for which have been reported previously (McMillan 2001; McMillan et al. 2001; 
McMillan et al. 2003a; McMillan et al. 2003b)  
 
Study 1. Cross-sectional survey of GH-treated and non-GH-treated 
adults with GHD 
Recruitment procedures 
Recruitment procedures have been fully described elsewhere (McMillan et al. 2003b), but 
in brief they were as follows.  All participating patients had been diagnosed severely GH 
deficient as determined by an Insulin Tolerance or Pituitary Function Test in which insulin 
reduced blood glucose to ≤2.5 mmol/L with peak GH concentration ≤10 mU/L. All patients 
had either received GH-replacement therapy for at least six months immediately prior to 
the study or had not received GH treatment in the previous six months; were aged 
between 18-70 years; had received appropriate adrenal, thyroid and gonadal hormone 
replacement therapy as required by their hormonal condition, for at least 12 months prior 
to the study. Patients might have had adult or childhood onset of GHD. Exclusion criteria 
were diabetes mellitus, active malignancy or pregnancy.  
 
Statistical analyses  
Combining the patient recruitment/ treatment subgroups 
There were four recruitment/ treatment subgroups: (1) GH-treated/ archive (names 
identified from the hospital database and approached by mailshot); (2) GH-treated/ clinic 
(patients identified at clinic and approached personally or via mailshot); (3) Non-GH-
treated/ archive; (4) Non-GH-treated/ clinic.  It was necessary to determine whether these 
four samples could be treated as one for the purposes of factor and reliability analyses 
where larger sample size is desirable. The procedure adopted was that used in the 
development of the ADDQoL where data also came from several sources (Bradley et al. 
1999). HDQoL item scores were first converted to z scores for each recruitment subgroup 
and then recombined. All questionnaire items were forced onto one factor in a Principal 
Components Analysis of (1) raw scores and (2) the recombined z scores, and loadings 
then compared by regression analysis. 
 
Normality issues 
Normality of distributions was investigated through histograms and standardised z(skew) 
values where z(skew) scores between ±2.58 are indicative of normality (Tabachnik & Fidell 
1983).  The HDQoL is not a questionnaire where a normal spread of scores and normal 
distributions would be expected as the bi-polar scale allows for some respondents having 
positive scores, indicating their perception that hormone deficiency had some positive 
effects on their lives, but positive scores were expected to be uncommon.  Ideally data 
should be normal for reliability and factor analyses.  However, finding transformations for 
skewed variables that did not adversely affect normal distributions of other items in the 
questionnaire proved difficult. Item data were not transformed to normality, thereby 
sacrificing some of the accuracy of reliability and factor analyses for the convenience of 
having interpretability of original units.  The assumption was made that if reliability were 
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high, the factor analysis robust, and the number of respondents sufficiently high, then a 
degree of non-normality was acceptable.  
 
Internal consistency reliability and factor structure 
Cronbach’s alpha coefficient (Cronbach 1951) was determined, with an acceptable 
minimum alpha being taken as 0.7 to 0.8, depending on the number of items in a scale 
(Todd & Bradley 1994), noting that some consider 0.9 as the minimum for measures of 
differences between individuals (Nunnally 1978). Acceptable item-total correlations are 
those >0.2 (Kline 1993). Factor structure was explored using Principal Components 
Analysis with Varimax rotation (to investigate the existence of any subscales), and a one-
factor solution was forced to confirm the validity of calculating the overall HDQoL AWI 
score. Salient loadings were taken as ≥0.5, higher than the recommended minimum 0.3 
(Kline 1994), erring on the side of caution in an effort to reduce the risk of spurious 
loadings that owed their origin to non-normality of item distributions and to avoid multiple 
loadings.  
 
The ‘Not Applicable’ response option and loss of data 
No data from any respondent selecting a N/A response option would normally be included 
in factor and reliability analyses, as SPSS treats N/A responses as missing data. 
Furthermore, if the SPSS default of listwise deletion of missings is used, all cases that 
have any missing values across all questionnaire items are lost to analysis, so 
considerable data could be lost. However, in preliminary psychometric analyses of the 
data set, when the N/A option was set to zero with pairwise deletion of missings [a method 
fully described for the original development of the ADDQoL (Bradley et al. 1999)] there 
was little difference from the results obtained using the default. Only results where SPSS 
default settings were used are reported.  
 
Sub group differences and ‘familywise’ error in multiple tests  
The questionnaire’s sensitivity to some sub-group differences was investigated (GH-
treatment groups, sex, age of onset of GHD). The Holm’s sequential Bonferroni procedure 
for multiple tests (Holm 1979) was adopted.  A minimum significance value of 0.017 was 
required if three similar statistical tests were performed on the HDQoL AWI, and overview 
items, QA and QB (regarded as one ‘family’), and a minimum significance of 0.004 if 
similar tests were performed on the 13 domains of the final questionnaire (another 
‘family’). 
 
Study 2. GH-Withdrawal study 
The HDQoL’s sensitivity to change was assessed in a randomised, double-blind, placebo-
controlled study where severely GH-deficient patients were allocated to placebo or 
continued treatment with GH for a period of three months. This study has been fully 
described elsewhere (McMillan et al. 2003a), and only a brief description follows.  
 
The HDQoL (in a battery of several questionnaires) was completed at baseline and end-
point, and a psychologist conducted semi-structured interviews with the patients at these 
points. There was a general clinical expectation of deterioration in physiological factors 
during the study period for those withdrawn from GH treatment and that this might be 
accompanied by reduced QoL.  It was therefore hypothesised that after three months’ GH 
withdrawal the Placebo group would exhibit more negative scores in HDQoL domains for 
which there had been significant findings in previous studies (using other questionnaires) 
 6
when patients had been given GH treatment (namely social life and physically do and in 
present QoL), but GH-treated patients would show little change.  
 
Means are reported as mean (standard deviation).  
 
Results (1: Cross-sectional study) 
The patient sample 
Of 219 questionnaires distributed, 163 were returned (74% response rate), but six patients 
did not meet all inclusion criteria, leaving 157 data sets, (91 GH-treated and 66 non-GH-
treated patients). Most patients (96%) had multiple pituitary hormone deficiencies including 
GHD; the remainder had isolated GHD. (See Table 1 for sample characteristics). 
 
(Table 1 here) 
 
The initial 18-item HDQoL 
Frequency analysis 
Completion rates for HDQoL impact and importance ratings were 97% and 96% 
respectively.  The data of four respondents with large amounts of missing data were 
excluded, leaving 153 HDQoL questionnaires for analysis. Numbers of participants 
selecting the N/A response option were as follows: working life: 21 (14%); family life: 6 
(4%); sex life: 17 (11%); religious life: 29 (19%). Only 13% of patients had a negative 
score for their present QoL (QA:present QoL), whereas 68% took a positive view of their 
current QoL, the remainder choosing ‘neither good nor bad’.  Most patients considered that 
their QoL would be improved if they did not have hormone deficiency, (QB:hormone 
deficiency-dependent QoL) (79%), but 7% indicated that it would be worse. 
 
Deletion of five items from the 18-item questionnaire   
On the basis of early frequency, reliability and forced 1-factor analyses, five domain items 
(religious life, society’s reaction, others fuss, living conditions and freedom to eat) were 
excluded from the questionnaire for the following reasons: 
• all five domains had severely negatively skewed distributions; 
• a relatively high proportion of respondents perceived hormone deficiency as having 
no impact on the domain [society’s reaction (67%), living conditions (72%), 
religious life (81%), freedom to eat (71%), others fuss (40%)], or that the domain 
was not important [religious life (24%), others fuss (19%)]; 
• low loadings (<0.42) on the forced 1-factor analysis (religious life and freedom to 
eat). 
 
All further analyses were conducted with the shortened 13-item HDQoL. 
 
The 13-item HDQoL 
Analyses showed that the four recruitment/ treatment subgroups could be combined for 
the purposes of psychometric analyses where large N is desirable.  Regression analysis of 
the forced 1-factor loadings obtained for the raw scores against the recombined z scores 
showed no significant difference between the two sets of loadings.  The correlation of 0.99 
was close to a perfect 1, the constant (0.004) was close to zero [t(12) = 1.36, P >0.05] and 
the slope (0.95) was also close to 1 [t(12) = 21.8,  P <0.001].   
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 Reliability and factor analyses 
Cronbach’s alpha for the whole scale was 0.914 (N = 109). ‘Alpha if item deleted’ values 
(all ≤0.914) indicated that no item detracted from internal consistency reliability.  Corrected 
item-total correlations were also all satisfactory and ≥0.44, (Table 2). To assess the effects 
of missing data on HDQoL reliability, reliability analyses were run sequentially, deleting the 
strongest item each time, i.e. deleting the item having the lowest ‘alpha-if-item-deleted’ 
value and therefore contributing most to the scale’s internal reliability (Mitchell & Bradley 
2001). Calculation of HDQoL AWI was reliable at alpha = 0.9 with maximum one item of 
missing data, and reliable at alpha = 0.8 with up to five items missing.  
 
The single factor produced in a forced 1-factor analysis accounted for 51% of the variance. 
All 13 items loaded satisfactorily ≥0.5, (supporting the uni-dimensionality of the measure 
and calculation of HDQoL AWI score), (Table 3). Unforced analysis produced two factors, 
accounting for 39% and 20% of the variance respectively, with 10 items loading ≥0.5 on 
Factor 1, (Table 3). Three items (travel, finances, and dependence) loaded on Factor 2, 
however, Cronbach’s alpha for the Factor 2  ‘subscale’ was only 0.67, falling short of 
optimal reliability. Furthermore, travel (referring to problems with travelling) is negatively-
worded unlike the other 12 items. In more recent versions of the ADDQoL this item has 
been changed to be positively-worded and it now loads with the other items. It is expected 
that, if the wording were reversed to be positive on the HDQoL, the item would load on 
Factor 1. It was decided to retain the 13-item scale as one without any subscales, 
particularly as previous experience with the ADDQoL has not found subscales. 
 
It was concluded that: 
• the 13-item HDQoL was a reliable scale; 
• there were no useful subscales; 
• weighted items could be summed into an overall HDQoL AWI score. 
 
(Tables 2 and 3 here) 
 
Whole sample frequencies 
All 13 weighted domains had negative means, (indicating QoL was impaired by hormone 
deficiency), ranging from -1.2 (travel) to -3.08 (physical appearance), (Table 4). Hormone 
deficiency had most negative weighted impact on physical appearance, physically do, and 
sex life.  It had the least impact on travel, dependence and finances. The HDQoL AWI 
score for the whole patient group was mean (SD) -2.32 (2.22), N = 153, indicating overall 
negative impact of hormone deficiency on QoL. QA:present QoL score was 1.0 (1.23), N = 
152, indicating good QoL.  
 
(Table 4 here) 
Sub-group and correlational analyses  
Mann-Whitney tests found no significant differences between GH-treatment groups in 
HDQoL AWI or the two overview items. (Fig. 2 shows the domain weighted impact scores 
for the GH treated and untreated groups in the cross-sectional study).  GH-treated patients 
tended to have less negative weighted impact scores on every domain compared with the 
non-GH-treated group, indicating less negative impact of hormone deficiency. Whilst none 
of these differences was significant in itself, the fact that the between-treatment-group 
differences in all 13 domains were in the same direction was highly significant on a sign 
test (P <0.001). A significant positive correlation was found for QA:present QoL and 
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duration of GH treatment in the GH-treated group: [rho = 0.28, P = 0.009, N = 86] 
indicating improved QoL with longer duration of treatment.   
 
Women, median -2.38, had significantly lower scores than men, median -1.69, for HDQoL 
AWI [U = 2227.5, P = 0.012], for QB: hormone deficiency-dependent QoL (women, median 
-2.0 compared to men, median -1.0), [U = 2048.5, P = 0.002] and also for QA:present QoL 
(women, mean 0.79 (1.25) compared to men, 1.24 (1.16)); [t(149.8) = 2.33, P = 0.021] 
suggesting significantly greater negative impact of hormone deficiency on QoL and lower 
present QoL than men. There were no significant differences in AWI or the overview items 
between those with adult or childhood onset of GHD.  
 
There was a moderately high correlation between HDQoL AWI and QA:present QoL (rho = 
0.53, P <0.001, N = 152). The correlation between HDQoL AWI and QB:hormone 
deficiency-dependent QoL was higher, (rho = 0.71, P <0.001, N = 152), not surprisingly  
because both concern impact of hormone deficiency.   
 
(Fig 2 here) 
 
Results (2: GH-Withdrawal study) 
The data of 21 patients [age range 25-68 years], all but two with multiple pituitary hormone 
deficiencies, were available for analysis: 12 placebo-treated (6 men and 6 women) and 
nine GH-treated (4 men and 5 women). Three months after baseline the serum total IGF-I 
of placebo-treated patients fell from normal, age-related levels, mean 26.6 (13.2) nmol/L, 
to levels indicative of severe GHD, 11.6 (6.7) nmol/L, (P <0.001). Only a small, non-
significant decrease was noted in GH-treated patients.   
 
HDQoL completion rates dropped as the study progressed: impact ratings from 96.2% at 
baseline to 94.2% at end-point, and importance ratings from 93.1% to 91.9%. It was not 
possible to calculate HDQoL AWI for two placebo-group patients with more than five 
missing weighted domain scores as internal reliability was <0.8 with this amount of missing 
data. As the sample size was small, Bonferroni corrections were not applied in the case of 
variables for which direction of change was predicted to reduce the chance of Type II 
errors and as it was unlikely that a significant result would be obtained by chance. The 
required significance level was set at <0.05. 
 
Whilst GH-treatment group means exhibited some variation in direction of change over the 
study, placebo-group means showed a non-significant tendency to drop (indicating greater 
perceived negative impact of hormone deficiency by end-point) for HDQoL AWI, the 
overview items and for all domains except sex life and future (results not shown). As 
expected a significant between-group difference in change was found for domain 
physically do [t(16) = 2.47, P = 0.025, 2-tailed], with scores of placebo-treated patients 
dropping from -0.25 (3.02) at baseline to -1.80 (1.81) at end-point, (indicating greater 
negative impact of hormone deficiency on physical capabilities by end-point) while scores 
of GH-treated patients increased from -3.5 (2.51) at baseline to -2.38 (1.19) at end-point. 
Patients withdrawn from GH reported reduced physical capabilities at end-point.  
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Adding new domains to the HDQoL 
Owing to time constraints the HDQoL was initially developed without involving patients in 
item generation, but the questionnaire’s free comments section was designed to allow 
respondents to mention areas of life affected by their hormone deficiencies, and not 
already covered in the questionnaire. The free comments section (cross-sectional study) 
and data from patient interviews (GH-Withdrawal study) were analysed with a view to 
improving the content validity of the HDQoL. Ten domains were mentioned that are 
already covered in the HDQoL, (physical functioning, physical appearance, work, self-
confidence, sexual functioning, sociability, motivation/ mental drive, dependence, worries 
about the future and travel), which lend support to the content validity of the questionnaire; 
however, several additional domains were mentioned as follows. 
• Interviews: patients described key areas of improvement that they had noticed in the 
past on initiation of GH therapy, and those on placebo (GH-Withdrawal study) 
described areas of deterioration in QoL and functioning over the course of the study, 
particularly in energy, memory, sleep pattern, stress-tolerance, feeling depressed/ 
anxious and bodily pain.  
• Free comments analysis: energy, weight, bodily pain and feeling depressed/ anxious 
were most frequently mentioned. Table 5 provides details of the seven most frequently 
mentioned new domains that will be added to the 13-item questionnaire in the future to 
improve its content validity. 
  
(Table 5 here). 
 
Discussion  
The HDQoL is a new measure of the impact of hormone deficiency on QoL, and which is 
under continuing development.  It is individualised in that patients rate only relevant 
domains, and both the impact of the condition on life domains and the importance of each 
domain to their quality of life are taken into account in scoring. Being bi-polar it assesses 
both positive and negative ends of the QoL continuum, although this resulted, as 
expected, in skewed data distributions because few patients perceived any positive 
benefits of hormone deficiency on QoL. There were relatively high completion rates in the 
cross-sectional study although these fell over the course of the GH-Withdrawal study, thus 
the questionnaire had good acceptability to the majority of respondents – an indication of 
face validity. 
 
Psychometric analyses indicated that the original 18-item HDQoL, which had been 
adapted from the renal version, the RDQoL, would be improved by dropping five items. 
Internal consistency reliability, item-total correlations and factor analyses were supportive 
of the shorter 13-item HDQoL. There was insufficient evidence for subscales, but support 
for summing the 13 items into a single HDQoL Average Weighted Impact score. The two 
overview items are useful. QB, concerning impact of hormone deficiency on QoL, could 
replace the full HDQoL for some purposes, such as clinical audit, as the correlation 
between QB and overall HDQoL AWI was sufficiently high (0.71).  Furthermore, rich 
information can be obtained by analysing individual domains separately, and this could 
prove valuable in routine clinical monitoring and clinical trials, to ascertain the impact of 
hormone deficiency on specific aspects of life. For example, in the cross-sectional study, 
hormone deficiency had most negative impact on patients’ physical appearance, physical 
capabilities, sex life, family and working life. Averaging across domains, patients felt that 
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they would have better QoL if they did not have hormone deficiency, but that their current 
QoL was good.  
 
As might be expected, there were consistent trends (albeit non-significant) indicating that 
GH-treated patients perceived less impact of hormone deficiency than non-treated patients 
on each of the 13 domains, but the consistent direction of those trends on all domains was 
significant.  It seems, therefore, that there were no large differences in QoL of GH-treated 
and non-GH-treated patients in the cross-sectional survey, indeed none of the other 
questionnaires used in the study found GH-treated patients to have significantly better 
patient-reported outcomes (including health status and well-being) than non-treated 
patients (McMillan 2001).  It may well be that people prescribed GH treatment presented 
with more serious symptoms of mental and physical ill-health, compared with those who 
were not prescribed GH treatment, and might have had much worse QoL if they had not 
been treated. In one study, British patients who refused GH treatment had significantly 
better QoL-AGHDA median scores than those awaiting treatment, furthermore their scores 
were the same as for those receiving GH-treatment in Sweden and Germany (McKenna et 
al. 1999).  In the present study, only 11 of the 66 non-GH-treated patients eventually 
received GH replacement, once the survey was completed: the great majority were not 
awaiting treatment at the time of the survey.  
 
There was some preliminary evidence of construct validity in that there were significant 
correlations indicating improving current QoL with increasing duration of GH treatment.  In 
one study of longer-term GH treatment, well-being and health status were still improving 
even after periods of 20-50 months of treatment (Wiren et al. 1998). The HDQoL also 
found significant sex differences, with women showing greater negative impact of hormone 
deficiency on QoL than men, and reduced present QoL. This finding may also support the 
questionnaire’s construct validity. The literature shows that women in the general 
population have worse health status than men (Hunt & McKenna 1989; Brazier et al. 
1992), that there are substantial sex differences in physiological variables in untreated 
GHD (Burman et al. 1997) and that there are sex differences in responsivity to GH 
therapy, with a risk of under-treatment in women and over-treatment in men (Span et al. 
2000). All these factors may help explain the greater impact of hormone deficiency on QoL 
for women in comparison with men that were found by the HDQoL. The HDQoL did not 
find a difference in QoL between those with childhood and adult-onset of GHD, and this is 
in line with some other research (Abs et al. 1999).  
 
Despite the small sample size of the GH-Withdrawal study and resulting low power of 
analysis, the HDQoL exhibited some sensitivity to change in GH-deficient patients. There 
was a significant finding for physically do - a greater change in the Placebo group 
(withdrawn from GH treatment) than the GH-treatment group as predicted by hypotheses 
and indicating increased negative impact of hormone deficiency on physical capabilities for 
placebo-treated patients by end-point. There were similar, albeit non-significant, trends for 
the great majority of domains. The overall HDQoL AWI score showed no significant 
change, but the advantage of the questionnaire is that individual domains can be analysed 
separately, providing additional information. The lack of significant differences between 
GH-treated and non-GH-treated patients in the cross-sectional study and the lack of 
significant findings in the GH-withdrawal trial should not be considered evidence that GH 
treatment has no effect on QoL. Trends in the data were in the expected direction (less 
impact of hormone deficiency in GH-treated compared with non-GH-treated patients in all 
domains in the cross-sectional study; greater impact of hormone deficiency on placebo-
treated patients in most domains after three months’ GH withdrawal).  However, any future 
clinical trial of GH treatment to use the HDQoL needs a larger sample size to supply 
greater power of analysis. 
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Although the relevance of the 13 items of the HDQoL was confirmed (most domains 
mentioned by patients in the free comments section or during interviews are already 
covered in the questionnaire), qualitative work should ideally have been performed in the 
initial development of the questionnaire prior to first use (but was not, owing to time 
constraints). Qualitative work conducted during the study itself, however, has led to the 
consideration of seven new domains being added to the questionnaire: energy, weight, 
memory, sleep pattern, stress-tolerance, depression/ anxiety and bodily pain. Further work 
will now be needed to assess the properties of the extended 20-item scale and its 
sensitivity to change with bigger samples of patients with hypopituitarism.  
  
Conclusion 
The HDQoL is a new individualised measure of the impact of hormone deficiency and its 
treatment on QoL, where individuals complete only those items of relevance to their lives, 
and the importance of life domains to an individual’s QoL is taken into account in the 
scoring.  Although it is still at an early stage of development, the 13-item questionnaire is 
performing well and has good acceptability to the great majority of respondents, and good 
internal consistency reliability.  There is some preliminary evidence for construct validity 
and sensitivity to change. An overall score, the Average Weighted Impact score may be 
calculated and domains can be analysed separately if wished. Content validity may be 
improved by the inclusion of seven additional domains and further work is now needed to 
assess the properties of the extended scale and its sensitivity to change with bigger 
samples. Even at this present stage, the 13-item HDQoL appears to be a useful tool and is 
recommended for assessing impact of hormone deficiency on QoL in adult hypopituitarism 
including GHD.  
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 Legends 
 
Fig. 1: HDQoL domain item with scoring 
 
Fig. 2: Mean HDQoL weighted impact scores comparing GH-treated and non-GH-treated 
groups in the cross-sectional study 
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Table 1 Characteristics of the 157 patients in the cross-sectional survey  
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Table 2 Reliability analysis of the 13-item HDQoL  
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Table 3 Unforced and forced 1-factor analysesa of the 13-item HDQoL  
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37BTable 4 HDQoL. Wording and descriptive statistics (cross-sectional study) 
N
o
. 
Item wording… (response option) Abbreviation 
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id 
N 
Mean (SD) Ran
ge 
Medi
an 
Q
A 
In general, my present quality of life is …(as good as it could possibly be …. 
as bad as it could possibly be) 
present QoL 
 
15
2 
 1.00 
(1.23) 
-2 to 
3 
 1 
Q
B 
If I did not have hormone deficiency, my quality of life would be …(very 
much better …. very much worse) 
hormone 
deficiency-
dependent QoL 
15
2 
-1.36 
(1.40) 
-3 to 
3 
-1.5 
  
If I did not have hormone deficiency, … 
 
     
  
1
a 
…my working life and work-related opportunities would be …(very much  
better ….very much worse) 
work 
 
12
9a 
-2.64 
(3.34) 
-9 to 
9 
-2 
  
2
a 
…my family life would be …(very much better ….very much worse) family life 
 
14
4a 
-2.89 
(3.73) 
-9 to 
9 
-3 
  
3 
…my friendships and social life would be …(very much better ….very much 
worse) 
social life 
 
15
2 
-2.11 
(3.06) 
-9 to 
6 
-1 
  
4
a 
…my sex life would be …(very much better ….very much worse) sex life 13
6a 
-2.96 
(3.56) 
-9 to 
9 
-2 
  
5 
…my physical appearance would be …(very much better ….very much 
worse) 
physical 
appearance 
15
3 
-3.08 
(3.44) 
-9 to 
9 
-2 
  
6 
…the things I could do physically would be …(very much increased ….very 
much decreased) 
physically do  
 
15
3 
-3.01 
(3.03) 
-9 to 
9 
-3 
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N
o
. 
Item wording… (response option) Abbreviation 
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id 
N 
Mean (SD) Ran
ge 
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7  
…my holidays or leisure activities would be …(very much better ….very 
much worse) 
holidays/ 
leisure 
 
15
3 
-2.44 
(3.03) 
-9 to 
6 
-2 
  
8 
…problems with travelling (either local or long distance) would be …(very 
much decreased ….very much increased) 
travel 15
3 
-1.2 (3.15) -9 to 
9 
 0 
  
9 
…my confidence in my ability to do things would be …(very much increased 
….very much decreased) 
confidence 15
3 
-2.31 
(3.11) 
-9 to 
9 
-2 
1
0 
…my motivation to achieve things would be …(very much increased ….very 
much decreased) 
motivation 15
2 
-2.23 
(3.27) 
-9 to 
9 
-2 
1
1 
…my worries about my future and the future of others close to me would be 
…(very much decreased ….very much increased) 
future  15
0 
-2.48 
(3.71) 
-9 to 
9 
-2 
1
2 
…my finances would be …(very much better ….very much worse) finances 15
1 
-1.61 (2.9) -9 to 
9 
 0 
1
3 
…my need to depend on others for things I would like to do for myself would 
be …(very much decreased ….very much increased) 
dependence 15
0 
-1.45 
(2.84) 
-9 to 
9 
 0 
HDQoL © Prof Clare Bradley: 21.5.97. Health Psychology Research, Dept of Psychology, Royal Holloway, University of London, Egham, Surrey, TW20 
0EX, UK. 
aItem has a not applicable response option, with valid N reflecting the numbers who chose the N/A option. 
Maximum possible score ranges: QA:present QoL (+3 to -3), (from good to poor QoL), QB:hormone deficiency-dependent QoL (-3 to +3) (from maximum 
negative to maximum positive impact of hormone deficiency on QoL), 13 domain items (-9 to +9), (from maximum negative to maximum positive importance-
weighted impact of hormone deficiency on QoL). 
SD: standard deviation. 
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38BTable 5 Domains to be added to the 13-item HDQoLa 
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aNumbers of patients mentioning each domain either in the HDQoL free comments section 
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13BFigures 
 
 
 
Fig. 1: HDQoL domain item with scoring 
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 Fig. 2: Mean HDQoL weighted impact scores comparing GH-treated and non-GH-treated groups in the cross-sectional study 
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